
Sequencing CELMoDs and Integrating Treatment Strategies in Relapsed/Refractory Multiple Myeloma
Faculty discuss the potential role of CELMoDs in the evolving treatment landscape for relapsed/refractory multiple myeloma, including their mechanism of action, toxicity profiles, and potential impact on treatment sequencing.
Episodes in this series

Faculty discuss the potential role of CELMoDs in the evolving treatment landscape for relapsed/refractory multiple myeloma, including their mechanism of action, toxicity profiles, and potential impact on treatment sequencing. They consider how increased specificity for cereblon may influence antimyeloma activity and off-target toxicities, while emphasizing that further evidence is needed to establish meaningful differences among agents. The discussion explores the use of CELMoDs following CAR T-cell therapy and BCMA-directed bispecific antibodies, highlighting the need for effective combination strategies to achieve deeper and more durable responses in heavily pretreated patients. Faculty also consider whether CELMoDs should be viewed as an extension of the immunomodulatory drug class or as a distinct therapeutic class. Although structural and mechanistic differences may support using multiple agents throughout a patient’s treatment journey, the optimal sequence remains uncertain. The segment concludes with practical considerations for community practice, including oral treatment convenience, proactive growth factor support, infection prevention, and individualized treatment selection based on prior exposure and patient needs.
Related to this article








